A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Trial Profile

A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEAL; ZEST
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 16 Oct 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 12 Aug 2014 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top